Every one of those 1 sits in a single category, market-trends. ESS Tech, Inc. is most often covered alongside BioLargo, Inc., which appears in 1 of these 1 story. Source depth averages 5 original sources per story, versus 4.1 across the same-window beat baseline.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about ESS Tech, Inc.
Every one of those 1 sits in a single category, market-trends. ESS Tech, Inc. is most often covered alongside BioLargo, Inc., which appears in 1 of these 1 story. Source depth averages 5 original sources per story, versus 4.1 across the same-window beat baseline. Their average consequence score of 5 runs below the beat's 6 for that window. ESS Tech, Inc. appears in 1 tracked Healthcare story from March 9, 2026.
Stories tracked
1
Sources per story
5
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 30 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering ESS Tech, Inc.. Shared-story counts are live from our verified record — not editorial picks.
REGENXBIO and BioLargo reported Q4 2025 results marked by wider-than-expected losses, reflecting a challenging environment for high-growth biotech and environmental health firms. As REGENXBIO navigates the costly gene therapy pipeline, the broader market trend shows a tightening of fiscal performance across specialized technology sectors.